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Abstract 
The second most common cause of hospitalisation due to adverse drug reactions in the UK is 
renal dysfunction due to diuretics, particularly in patients with heart failure, where diuretic 
therapy is a mainstay of treatment regimens. Therefore the optimal frequency for monitoring 
renal function in these patients is an important consideration for preventing renal failure and 
hospitalisation. This review looks at the current evidence for optimal monitoring practices of 
renal function in patients with heart failure according to national and international guidelines 
on the management of heart failure (AHA/NICE/ESC/SIGN). Current guidance of renal 
function monitoring is in large part based on expert opinion, with a lack of clinical studies 
that have specifically evaluated the optimal frequency of renal function monitoring in patients 
with heart failure.  Furthermore, there is variability between guidelines, and 
recommendations are typically non-specific. Safer prescribing of diuretics in combination 
with other anti-heart failure treatments requires better evidence for frequency of renal 
function monitoring.  We suggest developing more personalised monitoring rather than from 
the current medication-based guidance.   Such flexible clinical guidelines could be 
implemented using intelligent clinical decision support systems. Personalised renal function 
monitoring would be more effective in preventing renal decline, rather than reacting to it.    
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Introduction  
 
Heart failure is an important cause of morbidity and mortality in the UK, and is likely to 
increase in prevalence as the population ages. Heart failure incidence overall is 1%, rising to 
around 12% in patients over 75 years.  It currently affects up to 900,000 patients in the 
UK.[1] These patients often suffer from co-morbidities including diabetes, COPD and 
ischaemic heart disease resulting in frequent hospital admissions and greater burden on the 
health service.[2] One of the most common causes of hospital admission and deterioration in 
these patients is worsening renal function.[3] Prevalence of chronic kidney disease (CKD) 
ranges from 39-60% in heart failure cohorts and is associated with increased mortality and 
morbidity.[4, 5]  Renal function can be overlooked due to lack of consensus on optimal 
timing and frequency of monitoring. NICE guidelines for management of chronic heart 
failure recommend a general rule of 6-monthly blood tests for urea and electrolytes in stable 
patients. However renal deterioration can occur rapidly and unpredictably and it is likely that 
monitoring is highly variable.  Clearer guidance for monitoring renal function may be helpful 
in reducing admissions by facilitating earlier intervention such as modification of drugs and 
their doses which may be contributing to the renal decline. Development of such guidelines is 
needed in this particular patient group because many drugs used in the treatment of heart 
failure contribute to renal decline.[6]  
 
Here we review reasons for renal decline in heart failure syndromes and explore the evidence 
for renal function monitoring, including optimal frequency.   
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Relationship between heart failure and renal failure 
 
An association between decline in cardiac function and renal function is well documented. 
Heart failure itself is associated with high risk of renal dysfunction and development of 
chronic kidney disease (CKD).[7-9]  Conversely, poor renal function has been shown to 
predict LV dysfunction.[10] This means that the onset of CKD is a risk factor for the 
subsequent development of heart failure.[11, 12] There is even evidence to suggest that eGFR 
correlates strongly with LV function well before any diagnosis of renal failure or heart failure 
has been made.[13-15] Indeed, up to a quarter of patients with CKD have symptoms 
suggestive of heart failure before a formal diagnosis is made.[16]  Collectively, the 
bidirectional link between cardiac and renal function can lead to clinical presentations that 
are termed cardio-renal syndrome (CRS).  
 
There are five types of CRS, the classification of which reflects the presumed primary and 
secondary problem.: [17] 
 
 Type 1: Acute heart failure causes acute kidney injury 
 Type 2: Chronic heart failure causes chronic kidney disease 
 Type 3: Acute kidney injury or acute renal failure causes acute cardiac failure 
 Type 4: Chronic kidney disease causes chronic cardiac dysfunction, including heart 
failure 
 Type 5: An acute or chronic systemic disorder causes both cardiac and renal failure 
(e.g. sepsis, diabetes mellitus, SLE) 
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The mechanism of renal injury in CRS is not clear but is likely to be multifactorial. The 
interaction between heart and renal failure can be described in terms of heart failure 
pathophysiology, renal responsive changes and the drugs to which patients are exposed. 
 
Heart failure pathophysiology causing renal decline 
Heart failure states cause increased central venous pressure (CVP). As the ventricles dilate 
and cardiac output decreases, pre-load increases, which is reflected in increased CVP. This 
venous back pressure can be transmitted to the renal vasculature causing chronic renal venous 
congestion, which in turn reduces glomerular blood flow by reducing the pressure gradient 
between afferent and efferent arterioles.[18] The observed association between high CVP 
states and fall in renal function is consistent with this paradigm.[19]  
 
In addition, right ventricular (RV) dilation in heart failure (which increases CVP) lowers 
cardiac output by several mechanisms. Firstly the direct effect of over-dilation causes 
decreased ventricular contractility (Frank-Starling Relationship). [20] Secondly, dilation of 
the RV impairs left ventricle (LV) filling by increasing LV extramural pressure, reducing LV 
functional volume and reducing preload (the reverse Bernheim phenomenon [21]). The 
resulting reduction in cardiac output decreases renal perfusion and measured renal function. 
 
Structural and responsive renal changes during heart failure 
Changes in renal perfusion are likely to account for much of the renal deterioration in patients 
with heart failure. However, the situation can be aggravated by drugs used to manage heart 
failure such as diuretics, which reduce intravascular volume and renal perfusion.[22]  
Compensatory mechanisms are activated to attempt to maintain intravascular pressure and 
preserve renal perfusion. Chronic compensation puts stress on normal regulatory systems 
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increasing risk of progressive failure. An important example is the renin-angiotensin-
aldosterone (RAA) system, which is activated by low renal arteriolar pressure, causing 
secretion of angiotensin, which promotes vasoconstriction, and aldosterone, which promotes 
sodium retention.[23] Long-term activation of the RAA system is harmful, consistent with 
the reduced mortality associated with ACE inhibitor use in patients with heart failure and 
their renoprotective effect in some types of nephropathy. The mechanism by which chronic 
RAA system activation causes harm is not clear, but contributing factors likely include 
systemic vasoconstriction which increases cardiac afterload, further reducing the cardiac 
output of a dilated heart. This leads to an even greater reduction in renal perfusion, causing 
further activation of the RAA system and a vicious cycle of deterioration.[24] 
 
Medications used in heart failure 
Drugs used to manage heart failure can reduce renal function by various mechanisms. This is 
particularly relevant in CRS types 1 and 2 where heart failure leads to renal failure. 
 
Loop Diuretics: These drugs promote natriuresis by reducing sodium reabsorption via the 
NKCC transporter in the loop of Henle, resulting in an efflux of water and reduction of 
intravascular volume. While this is beneficial for symptomatic heart failure with volume 
overload, it decreases total blood volume and thus reduces blood pressure contributing to 
renal hypoperfusion and compensatory systemic and renal vasoconstriction to maintain blood 
pressure. Since the function and perfusion of glomeruli rely on a constant flow from the renal 
arterioles, any reduction in flow in this way leads to renal decline, and if the patient’s 
compensatory mechanisms fail, it can quickly deteriorate into AKI. [25] 
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Thiazide diuretics: These drugs inhibit the sodium-chloride transporter in the distal tubule.  
Their hypotensive effects may also be useful for achieving BP targets in patients with IHD 
while the naturietic effect can have protective effects against pulmonary oedema. The 
hypokalaemic effect can counter-balance the potassium raising effects of ACEi/ARBs and 
potassium-sparing diuretics. [26, 27]   
 
As with loop diuretics, renal function can deteriorate acutely as a consequence of the 
hypovolaemia, resulting in AKI, or gradual progression of CKD. Hypokalaemia results from 
increased sodium delivery to the cortical collecting duct (CCT) with consequent increased 
uptake by the sodium epithelial channel ENaC and an increase in potassium excretion via the 
channel ROMK2 to maintain electrical neutrality. In addition, the diuretic induced naturesis 
causes upregulation of ENaC which is aldosterone-sensitive. Enhanced ENaC activity also 
increases cortical collecting tubule acid secretion which can cause metabolic alkalosis, which 
itself can be aggravated sometimes in renal failure because of impaired acid-base 
homeostasis.[28, 29] 
 
ACE inhibitors (ACEi) and angiotensin receptor blockers (ARBs): Many studies have 
shown a prognostic benefit of ACEi/ARBs in both heart failure and renal failure. Their effect 
on blocking the RAA system causes a predictable increase in serum creatinine because of 
their effect on intraglomerular haemodynamics. As serum creatinine currently remains the 
main biomarker for measuring renal filtration function, an acute decline in renal function 
might be apparent on initiation or dose escalation of these drugs. The extent of the rise in 
serum creatinine may indicate whether it is a physiological or pathological response, with a 
total rise of up to 20% generally considered acceptable. Combination of ACEi/ARBs with 
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other ‘high risk’ medications and a background of pre-existing renal disease may cause 
subsequent renal deterioration, if not titrated appropriately.[30, 31] 
 
Beta-Blockers: Bisoprolol is the most commonly used beta blocker in heart failure, and is 
known to improve prognosis, [32] probably through a combination of both sympathetic 
inactivation, resulting in downregulation of the RAA system, as well as reduction in 
endothelin-1 and thromboxane prostaglandins which promote vasoconstriction in response to 
sclerosis and injury. These effects result in renal arteriole vasodilation which improves blood 
flow and protects renal perfusion.[33]  Renal decline however can occur with beta-blockers 
due to a reduction in cardiac output, consequent to the bradycardia, which could reduce renal 
perfusion.[34, 35]  However, bisoprolol has largely been accepted as being safe over a long-
term period in renal failure.[36, 37] Indeed it continues to be of prognostic benefit even in 
renal decline, and this benefit is even greater in patients with the most severe stages of renal 
failure, without affecting overall eGFR significantly.[38] 
 
Calcium channel blockers: Heart failure patients often suffer from hypertension, especially 
if the primary cause is due to ischaemic heart disease. These patients are likely to be 
prescribed hypotensive agents such as calcium channel blockers. By reducing systemic blood 
pressure, these agents may also carry a potential risk of reducing perfusion and filtration 
pressure through the kidney, causing renal ischaemia and decline in function over time.[39]  
However, in practice, amlodipine seems to have renoprotective effects in CKD patients, 
especially when paired with ARB blockers.[40, 41], probably due to a reduction in renal 
artery smooth muscle contraction leading to a higher renal flow, even while systemic blood 
pressure is reduced.[42] Indeed, even a single dose of amlodipine can lead to a demonstrable 
increase in eGFR in CKD patients.[43] 
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Aspirin: This is commonly used in secondary prevention of ischaemic heart disease because 
of its anti-platelet effects. Rarely aspirin can cause an idiosyncratic reaction causing tubulo-
interstitial nephritis (TIN), which can lead to AKI. This is rare at low doses of 75mg, 
although the risk is slightly higher if combined with other NSAIDs and analgesics.[44]  
Similar to other NSAIDs, aspirin at high doses can be nephrotoxic because of detrimental 
effects on renal prostaglandins. It can also cause fluid retention, which can exacerbate heart 
failure.[45] 
 
Aldosterone antagonists: Spironolactone and eplerenone have shown significant benefit in 
heart failure outcomes, but they can also lead to serious adverse effects. As with loop and 
thiazide diuretics, they can increase risk of dehydration and hypoperfusion. They also cause 
potassium retention which can lead to hyperkalaemia, the risk being higher in CKD. 
Hyperkalaemia increases risk of arrhythmias, morbidity and mortality. Concurrent use of 
aldosterone antagonists with ACEi increase risk of hyperkalaemia and so should be used with 
caution.[7] 
 
Digoxin: This is now used infrequently in patients with heart failure, and is used mainly in 
patients with concomitant atrial fibrillation. Digoxin has positive inotropic and negative 
chronotropic effects.  There have been very few studies of the effects of digoxin on renal 
function in patients with heart failure and CKD, but it seems to have no effect on renal 
dysfunction in small doses.  Conversely, since digoxin excretion is mainly renal, 
accumulation can occur in severe kidney dysfunction, leading to digoxin toxicity and 
potentially cardiac arrhythmias.[29] 
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Hydralazine and Nitrates: These drugs both increase nitric oxide (NO) availability in blood. 
NO is a potent vasodilator of systemic vasculature which lowers blood pressure and 
potentially increases renal arterial flow. This effect has been demonstrated during intravenous 
administration in an acute setting.[46] ISDN combined with hydralazine has been shown to 
decrease mortality in patients with renal failure.[47] Hydralazine can rarely cause drug-
induced lupus, which can also involve the kidneys leading to renal dysfunction.[48] 
Hydralazine is renally excreted and can accumulate in patients with CKD.[49] 
 
Ivabradine: This is used to reduce heart rate in patients already taking beta blockers, who 
remain symptomatic. This drug acts on the If sodium channel in the sino-atrial node to delay 
repolarisation. Only 20% of ivabradine is renally excreted, with no known associations with 
renal pathology making it unlikely to pose a renal risk.[32] 
 
The biomarker manifestations of renal decompensation 
 
Acute kidney injury (AKI) is a rapid deterioration in renal function, usually over days to 
weeks. It is defined arbitrarily by a rise in serum creatinine or a fall in urine output, according 
to internationally accepted criteria such as the KDIGO classification. In clinical practice it is 
far more common to use the serum creatinine criteria, as hourly urine output is rarely 
recorded routinely outside intensive care and renal units. AKI is first defined as an increase in 
serum creatinine by 50% from baseline within 7 days, or an absolute increase in creatinine by 
26.5 µmol/l over 48 hours, or the presence of acute oliguria (<0.5 ml/kg/h for 6 hours).[50]  It 
is then staged (1-3) by further specific creatinine or urine output criteria. AKI can progress to 
more severe forms with oliguria and need for renal replacement therapy. AKI is a common 
cause of hospital admission for patients with heart failure. In many cases the development of 
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AKI, or increase in its severity, may be preventable with appropriate monitoring of renal 
function and adjustment of prescribed drugs. Earlier detection of AKI by laboratory or 
clinical parameters allows earlier intervention and probably increased chance of prevention or 
amelioration. 
 
One early warning system is the clinical classification of Worsening Renal Function (WRF). 
WRF is a state of pre-AKI which is specific to heart failure patients. It has a more gradual 
biomarker (creatinine) increase than AKI, occurring over 6-12 months rather than 7 days, 
which makes it easier to detect on routine screening than the criteria for AKI.[51] WRF is 
associated with greater mortality, morbidity and hospitalisation rate attributable to both renal 
and heart failure. WRF acts as an early warning system for progression of renal impairment, 
and allows for earlier intervention so that hospital admission can be avoided. [52] 
 
There are various definitions of WRF described in the literature, generally accepted ones 
being: 25% increase in baseline creatinine; 26.5 µmol/l absolute increase in creatinine; or 
20% decrease in eGFR (estimated glomerular filtration rate). While these criteria are similar 
to AKI definition, the important difference is the much longer timescale. More recently, WRF 
has been divided into 3 classes based on severity of renal decline (Table 1)[24] increasing up 
to an outcome of AKI. 
 
The definition of WRF relies on biomarker change from an established baseline.[53] 
Therefore true risk of renal decline must take into account baseline renal function which is 
most commonly defined using eGFR formulae.[54, 55] This, in turn,  influences their risk of 
further deterioration (Table 2).[56] CKD is graded from G1 (Normal) to G5 (End-stage renal 
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failure), the greater the severity, the greater the risk of mortality from any cause, 
cardiovascular events and hospitalisation.[57] 
 
As heart failure progresses in patients, it is often accompanied by progressive CKD with a 
fall in eGFR.[9] The patient is at increased risk of WRF and subsequent AKI. This risk is 
usually compounded by the various drugs and systemic insults to which patients with heart 
failure are often exposed.[7, 58] An effective system of regular monitoring can help 
clinicians intervene at a stage sufficiently early to reduce risk of progression to kidney 
failure. 
 
Frequency of renal monitoring 
 
No study has specifically assessed frequency and optimal timing of renal function monitoring 
with respect to clinical outcomes in patients with heart failure. Various studies have 
emphasised the importance of frequent and regular monitoring of renal function but there is 
no evidence-based gold standard.[59, 60] 
 
To address optimal frequency, published heart failure management guidelines will be 
reviewed. Other relevant factors will then be taken into account such as renal 
pharmacodynamics, rate of renal decline, risk factors for renal decompensation and the time 
required for an intervention to have an effect. 
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Methods 
 
The following databases were searched for clinical guidelines for heart failure and studies of 
renal monitoring in heart failure: Cochrane Database of Systematic Reviews (CSDR), 
Database of Abstracts of Reviews of Effects (DARE), Cochrane Central Database of 
Controlled Trials (CENTRAL), MEDLINE, EMBASE, Web of Science and CINAHL. 
Studies of interest were further reviewed for inclusion of heart failure guidance. Selection of 
clinical guidelines was agreed by consensus of clinical investigators for relevance to this 
review. Cited studies within these publications were scrutinised. Search strategy for other 
related references can be found in the supplementary information (Appendix A). 
 
Nomenclature of Targets and Ligands 
Key protein targets and ligands in this article are hyperlinked to corresponding entries in 
http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY[61], and are permanently archived in the Concise Guide to 
PHARMACOLOGY 2015/16.[62]  
 
Renal function monitoring in current guidelines for chronic heart failure 
 
NICE guidelines for chronic heart failure in adults (Oct 2014) [1] 
 
The National Institute for Health and Care Excellence (NICE) clinical guidelines for the 
management of chronic heart failure advises a minimum frequency of 6-monthly monitoring 
for patients with stable CHF. Increased frequency (of “days to 2 weeks”) is recommended if 
changes are made to the drug regimen. More detailed monitoring is suggested for patients 
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with “significant comorbidities or deterioration” though this is not elaborated on further. 
These are relatively non-specific monitoring recommendations open to interpretation by 
clinicians. 
 
For ACEi and ARBs more specific guidance exists.  Checking baseline renal function on 
initiation of the drug is recommended, with dose titration 2-weekly, monitoring renal function 
each time until target dose is reached. Cross-referencing to NICE clinical guidelines for 
chronic kidney disease, renal function monitoring is advised 1-2 weeks after initiation or dose 
increment. More specific guidance for renal function monitoring in patients with heart failure 
is given in the appendices (“Appendix D of the NICE guideline for chronic heart failure”). 
Regular follow-up monitoring of renal function is advised every 3 months if the patient 
continues to take ACEi or ARBs. The guidance advises against use of these medications with 
baseline potassium >5 mmol/L and recommends discontinuation at ≥6 mmol/L. Maximum 
permitted fall in renal function after ACEi/ARBs initiation or titration is suggested to be 25% 
decrease in eGFR or 30% increase in creatinine from pre-treatment levels. ACEi or ARB 
dose should be reduced or the drug discontinued if these limits are exceeded. Any lesser 
degree of renal deterioration warrants further testing after 1-2 weeks, but the dose should not 
be decreased unless these limits are exceeded. 
 
The risk of hyperkalemia with aldosterone antagonists is emphasised with renal function tests 
suggested post-initiation at 1 week, then at 1, 2, 3, 6 months and then 6-monthly if stable. 
Dose should be halved if potassium reaches 5.5-5.9 mmol/L and stopped if it reaches 6 
mmol/L.  The guidance also advises frequent monitoring in patients taking loop and thiazide 
diuretics alongside aldosterone antagonists, as well as advising monitoring of potassium 
when digoxin is prescribed concurrently, but no frequency is specified. 
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In summary, the minimum monitoring frequency recommended by NICE is 6-monthly unless 
the patient’s condition or medication has changed, in which case the minimum interval is 
reduced to 2 weeks but can be more frequent at the discretion of the clinician. The rationale is 
that medication for heart failure can cause adverse effects such as dehydration and renal 
impairment that can manifest within 2 weeks. These recommendations were based on 
analyses of local data looking at incidence of renal impairment, hospital admission, re-
admission and length of stay in patients where medication had been changed.[1] 
 
Evidence used for these suggestions included a study from 1995 in which spironolactone 
added to ACEi and diuretics resulted in 4/28 patients having a significant rise in creatinine 
and hyperkalaemia. These changes occurred by first follow up at 4 weeks and were 
asymptomatic.  Therefore this study recommended weekly monitoring of renal function 
during initiation and titration of aldosterone antagonists for all patients. [63]  
 
Management and monitoring of ACEi, ARBs, beta-blockers and spironolactone in CHF were 
also addressed by McMurray et al.. Their recommendations were based on expert opinion and 
clinical safety trials published before 2001.[64]  These recommendations were adapted by the 
NICE Guideline Development Group and further updated in 2010 using evidence from NICE 
clinical guidance on management of chronic kidney disease.  
 
SIGN guideline on management of chronic heart failure (March 2016) [65] 
The Scottish Intercollegiate Guidelines Network also advises on monitoring of renal function 
in CHF. For ACEi and ARBs, renal function and electrolyte monitoring is recommended 1-2 
weeks after initiation or dose increase. Renal function should then be monitored “frequently 
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and serially until potassium and creatinine have plateaued”, but no specific frequency is 
suggested. 
 
Maximum acceptable increase in creatinine after ACEi or ARB introduction is considered to 
be 50% or 266µmol/L from baseline with a maximum acceptable serum potassium of 5.5 
mmol/L. If these limits are reached, other ‘high risk’ agents should be reviewed and 
discontinued first. If renal function does not improve,  ACEi or ARB dose should be halved 
before re-checking renal function after 1-2 weeks. If there is still no improvement, specialist 
opinion should be sought. At no point is there a recommendation to stop ACEi/ARBs and the 
only contraindications mentioned are angioedema and bilateral renal artery stenosis. 
 
For beta-blockers, renal function monitoring is also recommended 1-2 weeks after initiation 
or dose change. Dose should be reviewed in the event of hypotension, bradycardia, or fatigue 
but renal dysfunction is not specifically mentioned. 
 
Guidance regarding aldosterone antagonists is, as with NICE, more comprehensive due to the 
increased risk of hyperkalaemia. The recommendation is similar to that of NICE with renal 
function testing at 1 week, then at 2, 3, 4, 6 months then 6-monthly thereafter if stable. Dose 
should be halved with serum potassium of 5.5 mmol/L or above and stopped if above 6 
mmol/L. Monitoring with loop diuretics is mentioned but no specific time interval 
suggested.[65] 
 
It is worth noting that this SIGN guidance is also derived from McMurray et al.’s practical 
recommendations for heart failure, the same source used by NICE but follows it more closely 
than does NICE. This is apparent in the quoted maximum acceptable creatinine rise before 
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intervention is deemed necessary. NICE uses its own limit of 30% increase in creatinine 
compared with McMurray’s (and SIGN’s) 50% increase from baseline. It is clear from the 
wording of the publication by McMurray et al that the higher threshold was designed to 
prioritise prescription of ACEi, ARBs and cardiovascular outcomes in heart failure rather 
than discussing renal decompensation.[66] 
 
ESC guidelines for the diagnosis and management of acute and chronic heart failure 
(May 2016) [67] 
 
The European Society of Cardiology guidelines acknowledge the high prevalence of CKD in 
HF and the frequent onset of WRF as a risk factor for future morbidity, AKI and hospital 
admission. They advise caution when using thiazide and loop diuretics in the context of 
declining renal function, but they encourage continuation of ACEi and ARBs unless there is a 
“large decrease” in renal function as a result. 
 
Supplementary information provides some drug-specific monitoring advice. For ACEi and 
ARBs, testing is advised 1-2 weeks after initiation and then 1-2 weeks after final titration 
only (which may be up to 5 dose titrations later).  However they note that blood chemistry 
should be monitored “frequently and serially until creatinine and potassium have plateaued”. 
When stable, regular monitoring is suggested at 4-monthly intervals. Maximum accepted rise 
in creatinine is 50% or 266µmol/l from baseline. Deterioration above this level should trigger 
a review of other high risk medicines followed by halving of the dose of ACEi or ARB with 
repeat renal function check after 1-2 weeks. ACEi and ARBs should be discontinued if 
creatinine increases by 100% or more, or 310 µmol/L or if eGFR drops below 20 
ml/min/1.73m
2
 or if potassium exceeds 5.5mmol/L. 
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For aldosterone antagonists, ESC advises renal function and electrolyte checks at baseline,  1 
week, then 1, 2, 3, 6, 9 and 12 months after initiation, then 4-monthly when stable. For 
hyperkalaemia, they advise halving the dose at 5.5mmol/L and discontinuation at 6mmol/L.  
 
For diuretics, ESC recommends renal monitoring at baseline, then 1-2 weeks after initiation 
or dose change. Discontinuation of diuretics is recommended in the event of worsening renal 
impairment or dehydration. 
 
The ESC recommendations are based predominantly on expert opinion. No specific 
references are given with respect to renal monitoring, although they are similar to NICE and 
SIGN guidelines. (Table 3) 
 
ACCF/AHA guideline for the management of heart failure (October 2013) [68] 
 
A pragmatic approach to diuretic prescribing is described. It is suggested that furosemide, the 
most common diuretic in HF, is titrated up based on daily weight of the patient to achieve 
daily weight loss of 0.5-1.0 kg, followed by a lower maintenance dose to keep weight at the 
target. The dose can then be adjusted in primary care or by the patient, as necessary, over the 
longer term. For ACEi and ARBs, advice is to start at a low dose then monitor renal function 
after 1-2 weeks then “periodically thereafter” according to the clinician’s judgement, 
including after dose increases. Risks of renal decline in patients with diabetes and 
hypertension are noted. 
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For aldosterone antagonists, a more stringent monitoring regimen is advised, with the option 
of an alternate day starting dose for patients with CKD and monitoring after 2-3 days then at 
7 days for all patients. Thereafter monthly monitoring is advised every 3 months if renal 
function is stable.  This monitoring schedule should then be repeated every time the dose 
changes. 
 
Sources of this guideline included 9 trials involving ACEi, 6 relating to ARBs, 25 to diuretics 
and 5 to aldosterone antagonists. The guideline also cross-referenced ESC and NICE 
guidelines. 
 
Compared with other guidelines, advice on renal monitoring is less specific though there is 
generally a more cautious approach with respect to the risk of worsening renal function. 
ACEi and ARB guidance is similar to other guidelines but a more cautious approach is 
adopted to aldosterone antagonists. This reflects the high risk of hyperkalaemia observed in 
its referenced studies reaching up to 36% in certain population based registries and an 
associated increase in mortality.[69] These findings are supported by the UK national heart 
failure audit, which lists serum potassium >5.5 mmol/L as the main predictor for mortality in 
inpatients with heart failure.[2] This encourages a stricter schedule of electrolyte monitoring 
with aldosterone antagonist prescription, which is mirrored in this guideline.  
 
Heart failure medications, renal effects and monitoring according to guidelines 
 
Diuretics 
Despite widely acknowledged potential detrimental effects of loop and thiazide diuretics on 
renal function, only the ESC guidelines provide specific monitoring advice regarding their 
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use in heart failure. This contrasts with guidance regarding aldosterone antagonists, which is 
comprehensive and specific in each guideline, reflecting evidence for risk of hyperkalaemia, 
which is a predictor of mortality.[70, 71]  Furthermore, prolonged use of spironolactone in 
patients with heart failure can increase risk of developing CKD, leading to this potassium-
sensitive state much sooner.[7]  Stringent monitoring systems are therefore justified for this 
drug class. 
 
With loop diuretics, the risks may actually be at least as great as with aldosterone antagonists.  
In patients with heart failure, use of loop diuretics is associated with more severe renal 
decline, higher risk of hospital admission and increased mortality rate. The renal decline is 
dose-dependent with higher doses causing more rapid decline in eGFR.[7, 72] This 
association is increased in patients with WRF, causing even greater risk of mortality and 
dose-dependent renal decline.[73] It is not surprising then that increased use and requirement 
for both loop and thiazide diuretics are associated with increased risk of end-stage renal 
disease.[7, 74]  
 
Paucity of renal function monitoring guidance for loop and thiazide diuretics, compared with 
aldosterone antagonists, likely relates to the fact that trials of the latter were conducted 
relatively recently. Lack of guidance for renal monitoring with diuretics may partially explain 
why diuretics are the second most common cause for U.K. hospital admissions due to adverse 
drug reactions.[6] If patients at highest risk of renal decline are given the highest doses, 
without specific monitoring advice, poor outcomes are not surprising. These risks should be 
emphasised as much for diuretics as for aldosterone antagonists, in current guidelines. 
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Pharmacokinetic studies show that different diuretic agents have different durations of action 
in patients with heart failure, with different times from initiation to observed pharmacological 
effect (Table 4).  Studies looking at the timed response to the loop diuretic bumetanide have 
shown that its diuretic effect occurs less than one hour after oral administration. Maximal 
effect is achieved after the first dose, with diminishing effect of subsequent oral doses (up to 
25% less than the first dose for the same concentration).[75] These findings are supported by 
observed actions of the loop diuretic furosemide, which shows a maximal effect within 1.5 
hours of the first oral dose and reduced effect with the same dose given repeatedly.[76]  A 
similar effect has been seen with the thiazide diuretic hydrochlorothiazide.[77] The greatest 
diuretic effect is seen with the first few doses, causing significant electrolyte shifts within the 
first 3 days of administration. This can lead to hypokalaemia, hyponatraemia and 
compensatory mechanisms for sodium retention, including aldosterone release, thus 
effectively counteracting the diuretic effect. A new steady state is achieved after about 2 
weeks where salt intake and natriuresis are balanced. 
 
These observations have implications for both diuretic dosing and monitoring of renal 
function. The greatest change in renal function biomarkers (such as serum creatinine) would 
be expected after the first dose and higher subsequent doses of the drug may be required for 
the same effect. In a patient with symptomatic heart failure, this may result in a progressive 
increase in diuretic dose with an accompanying greater risk of decline in renal function and 
AKI. This is compounded by the need for increasing doses of thiazide and loop diuretics as 
GFR falls.[57, 76] With reduced kidney perfusion, there is reduced rate of excretion of 
diuretic into the renal tubules which is required for these drugs to reach their sites of action. 
In addition, progressive nephron loss in CKD results in fewer sites at which the diuretics can 
act.[22] This not only reduces their effect as diuretics but also increases half-life in CKD, 
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which can cause ‘resistance’ to the diuretic so that increasing doses are required over 
time.[78] In addition, bioavailability of oral diuretics may be reduced in patients with heart 
failure because of the presence of gut wall oedema.[76] So patients with CKD and 
symptomatic fluid overload are faced with the highest initial risk of renal deterioration which 
is further increased by their need for higher doses of diuretics. Often this leads to hospital 
admission for administration of IV diuretics. 
 
No simple monitoring schedule is applicable for any one class of diuretic. Patient and drug 
factors are both important, with consideration of both the acute and maintenance phases of 
the diuretic action. A regimen of 1-2 weeks’ monitoring (recommended by ESC) may reach 
the steady state effect of the diuretic, but it does not take account of the risk of chronic slow 
deterioration in renal function. As discussed, monitoring of adequate frequency and duration 
is not reflected in current guidelines from NICE, SIGN and AHA, which rely predominantly 
on clinician judgement. 
  
ACEi, ARBs and anti-hypertensives 
The effects of ACEi and ARBs on renal function are well documented [52] and current heart 
failure guidelines emphasise the importance of renal function monitoring, suggesting no more 
than 2 weeks between initiation and first follow-up test. Slow titration is recommended at 2 
week intervals with close follow-up after dose changes. This strategy facilitates detection of a 
sudden fall in renal function after drug initiation or a progressive deterioration with dose 
increments. Higher doses of ACEi are associated with risk of greater acute rises in creatinine 
over the first 4 months of therapy so relatively frequent monitoring is justified over this 
period.[79]  Some studies advocate monitoring within 3-7 days of initiation of ACEi, to 
capture the first dose effect. This may be particularly relevant in patients with CKD (or 
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transiently impaired renal function) and high baseline serum potassium, where there is 
relatively high risk of hyperkalaemia which can increase risk of mortality.[80]  For this 
reason, the guidelines do advise caution for such patients. While the monitoring advice 
during the titration period is appropriate, the risks of first dose effects could be better 
observed with earlier follow up after initiation such as post-first dose monitoring. 
 
For beta-blockers and other anti-hypertensives which may be used in heart failure, only SIGN 
provides specific advice on renal monitoring. Other guidelines discuss symptomatic side-
effects of beta blockade such as dizziness, fatigue and hypotension but do not advise 
specifically on monitoring of renal function. This demonstrates one of the problems of a 
predominantly ‘medication-based’ prescribing (and monitoring) approach in a complex 
condition such as heart failure. 
 
‘Medication-based’ versus ‘Patient-based’ monitoring 
  
The approach of current heart failure guidelines to renal function monitoring can be described 
as ‘medication-based’. With scarcity of evidence, much of the guidance reflects expert 
opinion or adverse effect data from clinical trials. No studies have specifically addressed 
optimal timing of renal function monitoring, which has contributed to the potentially 
confusing variation in the published medication-based guidance. 
 
For example, if a patient is taking a stable dose of spironolactone and then starts an ACEi, 
causing serum potassium to increase to 5.6, SIGN, ESC and ACCF would recommend 
halving of the spironolactone dose rather than review of the ACEi, even though the temporal 
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relationship might suggest that the ACEi was the main adverse factor for this individual 
patient. 
 
Linking monitoring guidance to individual drug classes disassociates it from the patient, so 
that if one particular drug is discontinued, the guidance is assumed to stop with it. This 
creates the danger that the role of the heart failure pathology itself in causing renal 
deterioration will be ignored. Monitoring may become more concerned with detection of 
adverse effects rather than detection and reduction of progressive decline in renal function. 
This is reflected in current guidance for patients with apparently stable renal function, where 
only NICE has specific advice (of 6-monthly testing). This does not take account of 
individual patient risk factors such as age and co-morbidities. 
 
In addition, guideline development is complicated by the fact that most patients with heart 
failure are prescribed multiple drugs (ACEi, spironolactone, loop diuretics, beta blocker etc). 
Few studies have addressed the effect of such complex combinations on renal function in the 
medium-long term. For those studies that have, exclusion criteria might render the 
conclusions inapplicable to many patients with co-morbidities.  
 
To rationalise guidance for monitoring of renal function and to minimise risk of WRF and 
AKI in vulnerable patients, a ‘patient-based’ monitoring regimen should be developed. This 
would consider both medication and individual risk factors, and suggest a monitoring interval 
based on a patient’s combined risk, facilitating early intervention (such as dose adjustment) to 
reduce risk of renal deterioration, hospital admission and mortality. 
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Limitations of monitoring renal function 
 
Serum creatinine has, for decades, remained by far the most widely used assay for measuring 
renal function in primary and secondary care. It is a product of normal striated muscle 
turnover and is a marker of renal filtration function rather than of acute renal damage, 
because to a large extent it is filtered freely by the glomerulus. Despite the longevity of this 
assay, creatinine is far from ideal as a marker of renal function. Firstly it does not increase 
linearly with fall in GFR; indeed GFR can fall significantly below normal with little or no 
increase in serum creatinine. Secondly, it is also inaccurate at low GFR because the small 
degree of active tubular secretion of creatinine can confound the serum level. Conversely, 
drugs such as trimethoprim can cause spuriously high serum creatinine by blocking its 
tubular secretion. Thirdly, creatinine is a particularly poor marker of renal function at 
extremes of muscle mass. A serum creatinine of 130 µmol/L might represent normal GFR in 
a young person with high muscle mass or very low GFR in an older malnourished person. 
It is also essential to understand that, while increase in serum creatinine over time suggests 
deterioration in renal function (and defines AKI and its stages), it does not provide any 
information on the underlying renal pathology. To take contrasting examples, a 50% increase 
in creatinine from baseline might result from dehydration, with no histological changes, or it 
might result (albeit rarely) from an intrinsic renal pathology such as glomerulonephritis. 
Clearly the clinician needs to apply clinical context and common sense to interpretation of the 
creatinine result. Identification of more specific blood and urine biomarkers for renal injury 
and function is currently highly topical and of commercial interest but none is likely to be 
used widely in the next few years. 
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Estimated GFR (eGFR) is derived from serum creatinine using formulae which include age, 
gender and ethnicity. Different formulae are described, the most commonly used being 
MDRD and CKD-EPI.   A key point about use of eGFR is that it was developed and 
validated in populations with steady or slowly declining renal function. It is valid to use 
eGFR to monitor renal function over months and years, but for more acute changes in renal 
function, serum creatinine should be used. 
 
In monitoring renal function in the context of initiation and titration of drugs, often the trend 
in creatinine (or eGFR over months) is more important than the absolute value. A serum 
creatinine rising from 100 µmol/L to 200 µmol/L over 6 months following introduction and 
titration of a drug is likely to be of greater concern than a serum creatinine that has remained 
stable at 220 µmol/L over the same period.   
 
Clinical factors which impact WRF 
Personal risk factors other than medication need to be considered for effective patient-based 
monitoring. These include gender, age, smoking status and co-morbidities such as diabetes 
and CKD.[24]  By combining demographic factors such as gender and ethnicity with clinical 
history and co-morbidities, risk can be assessed more comprehensively than by considering 
only the drug regimen.  Decision rules have not been developed for patients in the community 
with heart failure presumably because of the complexity of dealing with multiple risk factors.  
The lack of data from sufficiently large cohorts has also been a limiting factor, but may be 
easier with increasing adoption of electronic patient records. 
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Rate of renal decline 
Rate of renal decline is itself a risk factor for further renal deterioration. Serum creatinine 
results inevitably fluctuate in patients with heart failure, often because of changes in their 
cardiac condition and associated changes in their drug regimen. Co-morbidities and other 
acute illnesses may also contribute to variation of creatinine between time points. However, 
the underlying or ‘baseline’ renal function nearly always declines over years, as is the natural 
history of most aetiologies of CKD. The average annual fall in eGFR over 4 years can be 
used as a measure of the rate of long term decline [59], and can act as a prognostic indicator 
for both the heart failure and the renal outcome. For example, a rapid decline in baseline renal 
function is associated with increased risk of incident heart failure, before the diagnosis of 
heart disease.[81, 82]  Furthermore, patients with higher rate of renal decline have higher risk 
of mortality associated with heart failure compared with those with a slower renal 
decline.[83, 84]  There might therefore be some benefit in standardisation of this rate of 
decline, to facilitate risk stratification.  
 
Timing of intervention (Intervention Lag) 
This is the time taken from initiation of monitoring of renal function to a change in clinical 
management to avoid an undesirable outcome. Typically this would simply involve the time 
taken for a patient to come back to clinic for a blood test, the waiting time for the result and 
the subsequent action which might involve another clinic visit or telephone call. In primary 
care this can be time consuming, especially if it relies on transportation of blood samples to a 
hospital laboratory.  With further time for patient recall, the intervention lag could range from 
2 – 5 days. The delay could be reduced with telephone follow up and use of recent advances 
in telemonitoring of clinical symptoms and signs.[85]  Taking this intervention lag into 
account is essential in planning a monitoring schedule. 
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Personalised monitoring guidance – a new perspective 
By incorporating a patient’s drug regimen, personal risk factors, baseline renal function and 
time required to intervene, a flexible monitoring system could be developed to improve renal 
outcomes in patients at high risk.  Simply increasing frequency of renal monitoring for all 
patients with heart failure would have significant cost implications and is unrealistic in a 
publicly funded health service.  Identification of patients at greatest risk of renal decline 
together with more efficient monitoring systems is likely to be the most cost-effective way of 
improving outcomes including hospital admission.  
 
This type of personalised care requires an automated system to analyse individual risk factors 
and derive clinical guidance for each patient. This could be aided by recent advances in 
machine learning and virtual-intelligence-aided clinical-decision-tools, which allow both 
rapid and intelligent assessment of biomarkers for clinical use.[86] For example, predictive 
analytics may be able to identify trends in eGFR and predict onset of WRF, calculating 
optimal monitoring time intervals and advising on dose adjustments to protect renal function. 
This personalised monitoring would take into account both early effects of medication 
changes and chronic effects of the disease process. Since it would be based on the individual 
patient, it would use cumulative data to improve its predictive accuracy with time.[87] 
Advances in remote care will help by bridging the gap between patient and clinician. This 
concept can be illustrated by the current work being developed by Google Deepmind’s 
‘Stream’ application, which collates hospital data from numerous sources, and uses predictive 
analytics to identify patients at highest risk of deterioration, allowing early intervention to 
avoid AKI in hospital inpatients.[88]  Allowing potential real-time monitoring of renal 
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function and instant medical feedback in this way would result in safer drug prescribing and 
lower risk of renal complications. [89] 
Conclusion 
 
Renal dysfunction contributes substantially to morbidity and mortality in patients with heart 
failure.[90] Current national and international CHF guidelines on renal function monitoring 
focus on drugs and their potential adverse effects, but offer less specific advice about 
monitoring of renal function. This reflects a paucity of data from adequately powered clinical 
studies. Risk factors for deterioration of renal function in CHF have been identified and could 
be incorporated into a ‘patient-based’ approach to monitoring.  
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Table 1: The accepted biomarker definitions of worsening renal function (WRF) classes 
compared to Kidney Disease Improving Global Outcomes (KDIGO) Acute Kidney Injury 
(AKI) definition [50, 60] 
 WRF Class I WRF Class II WRF Class III AKI 
% increase in 
creatinine  
 25%  50% (over 7 
days) 
Creatinine raw 
value increase 
(µmol/l) 
17.7 – 26.5 26.5 – 44.2 >44.2 >26.5 (over 48 
hrs) 
eGFR raw 
value decrease 
(ml/min/1.73m
2
) 
5 - 11 11 - 15 >15 - 
% decrease in 
eGFR  
- 20% - - 
Timescale 6 – 12 months 6 – 12 months 6 – 12 months 7 days/48 hrs 
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Table 2: Grading of CKD definitions based on baseline eGFR (KDIGO CKD definition) 
[57] 
GFR category GFR (ml/min/1.73m
2
) Renal function 
G1 >89 Normal or High 
G2 60-89 Mildly decreased 
G3a 45-59 Mild – moderate decrease 
G3b 30-44 Moderate – severe decrease 
G4 15-29 Severely decreased 
G5 <15 Kidney failure 
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Table 3: Summary and comparison of clinical guidelines relating to renal function 
monitoring in chronic heart failure patients under different circumstances. 
 NICE SIGN ESC ACCF/AHA 
Stable 6 monthly  Non-specific Non-specific Non-specific 
Clinical 
deterioration 
Days – 2 weeks 1-2 weeks Non-specific Non-specific 
Change in 
medications 
Days – 2 weeks 1-2 weeks Non-specific Non-specific 
Digoxin Non-specific Not mentioned Non-specific Non-specific 
Aldosterone 
antagonist 
1 week, then 1, 2, 3, 
6 months, then 6 
monthly if stable 
1 week, then 1, 2, 
3, 6 months, then 6 
monthly if stable 
1 week, then 1, 2, 
3, 6, 9, 12 months, 
then 4 monthly if 
stable 
2-3 days, 7 days, 
then monthly for 3 
months, then 3 
monthly if stable 
ACEi/ARBs At initiation, 2 
weeks, then every 3 
months when stable, 
every dose change 
1-2 weeks after 
initiation or dose 
change 
1-2 weeks after 
initiation and 1-2 
weeks after final 
dose titration, then 
4 monthly when 
stable 
1-2 weeks after 
initiation or dose 
change 
Threshold for 
reviewing 
ACEi/ARBs 
or 
aldosterone 
antagonist 
Creatinine: >30% 
increase  
eGFR: >25% 
decrease 
 
Creatinine: >50% 
increase or 
>266umol absolute 
increase 
Potassium:  >5.5 
mmol/L 
Creatinine: >50% 
increase or 
>266umol absolute 
increase 
Potassium: >5.5 
mmol/L 
Development of 
WRF (Creatinine 
>25% increase) 
Potassium: >5.5 
mmol/L 
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Loop Diuretic Non-specific Non-specific At initiation, then 
1-2 weeks after 
initiation and each 
dose change 
Non-specific 
Thiazide 
diuretic 
Non-specific Non-specific At initiation, then 
1-2 weeks after 
initiation and each 
dose change 
Non-specific 
Hypotensives 
(beta 
blockers) 
Not mentioned 1-2 weeks after 
initiation or dose 
change 
Not mentioned Not mentioned 
CKD + 
ARB/ACEi 
At initiation, 1 
week, 2 weeks, dose 
changes 
Non-specific Non-specific Non-specific 
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Table 4: Duration of action of diuretic agents used in heart failure [68] 
Loop Diuretics Maximum Daily Dose Duration of action 
Bumetanide 10 mg 4 – 6 h 
Furosemide 600 mg 6 – 8 h 
Torsemide 200 mg 12 – 16 h 
   
Thiazide Diuretics Maximum Daily Dose Duration of action 
Chlorothiazide 1000 mg 6 – 12 h 
Chlorthalidone 100 mg 24 – 72 h 
Hydrochlorothiazide 200 mg 6 – 12 h  
Indapamide 5 mg 36 h  
Metolazone 20 mg 12 – 24 h 
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List of Hyperlinks for Crosschecking 
 
 angiotensin 
 aldosterone 
 NKCC transporter 
 sodium-chloride transporter 
 sodium epithelial channel ENaC 
 ROMK2 
 Bisoprolol 
 endothelin-1 
 thromboxane 
 amlodipine 
 aspirin 
 Spironolactone 
 eplerenone 
 Digoxin 
 NO 
 ISDN 
 hydralazine 
 ivabradine 
 furosemide 
 bumetanide 
 hydrochlorothiazide 
 
 
 
